US › Healthcare

Context Therapeutics Inc (CNTX)

US · Healthcare · Biotechnology

$0.24+1.24%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-14.6M

EPS

$-0.15

EPS estimate

$-0.10

EPS came in at -0.15 against a street estimate of -0.10 — a miss of 50.0%.

Key statistics

Market cap

$25.3M

Forward P/E

0.0

P/B

0.93

Book value

$0.41

EPS (TTM)

$-0.44

52-week high

$3.62

52-week low

$0.25

50-day MA

$0.41

200-day MA

$1.54

Beta

1.72

Analyst view

Analysts rate Context Therapeutics Inc a strong buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $4.03.

Shareholding

Insiders

1.57%

Institutions

68.71%

Largest institutional holders

Fund	Stake
Deep Track Capital, LP	8.08%
Nextech Invest, Ltd.	8.08%
Soleus Capital Management, L.P.	7.69%
BlackRock Inc	6.71%
Avidity Partners Management LP	5.44%
Franklin Templeton Inc	4.14%
Vanguard Capital Management, LLC	3.74%
Octagon Capital Advisors LP	3.32%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Context Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.